Saffron for perimenopause mood: the useful bit, and the gap

One cup of saffron rice is not a mood-support dose. The supplement studies use concentrated saffron stigma extracts, often 30 mg a day, and the brand name matters because a tin of spice cannot be mapped milligram for milligram onto a trial capsule.

The most useful perimenopause evidence is also modest. In a 12-week randomised, placebo-controlled trial, 86 women with menopausal complaints took 14 mg Affron saffron extract twice daily, 28 mg total. The saffron group improved more on psychological symptoms, but not on vasomotor symptoms, somatic symptoms or the other reported quality-of-life measures. No major adverse events were reported.[1]

Saffron earned a narrow place in the conversation. It did not earn the job of explaining your hormones.

Short answer

Saffron may modestly improve some mood symptoms during perimenopause. The best directly relevant study used 28 mg/day of standardised Affron for 12 weeks and beat placebo on psychological symptoms. That is one 86-person trial, not a settled standard.

Other saffron mood trials studied adults with low mood or depression, not the menopause transition. They cannot automatically be transplanted to perimenopause. Our guide to supplements for perimenopause mood keeps that distinction visible.

What the mood research actually says

A 2026 review pooled 34 randomised trials with 1,769 adults. Saffron reduced Beck Depression Inventory and Beck Anxiety Inventory scores, but had no significant pooled effect on the clinician-rated Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, or Profile of Mood States. The authors rated the evidence moderate and said clinician-rated effects need better trials.[2]

One Affron trial sharpens the dose story. In 128 healthy adults who self-reported low mood but did not have a depression diagnosis, 28 mg/day for four weeks improved the self-reported total mood disturbance measure versus placebo; 22 mg/day did not. The 28 mg group also reported less stress and anxiety and more vigour.[3] Both screening and outcomes relied on self-report, and two authors were affiliated with the extract maker, Pharmactive.[3][4]

That supports one short mood study, not every brand’s serving. It studied one standardised stigma extract in capsules.

Dose and duration: what matches the research?

The common saffron research dose in depression studies has been 30 mg/day, split into two doses for about six weeks. A 2019 review warned about publication bias and short studies.[5]

For the keyword that brought you here, 28 mg/day of Affron for 12 weeks is the most useful study-matched benchmark. “Saffron 30 mg” on a label is not automatically equivalent. Studies have used stigma extracts, petal products and crocin-only preparations, which do not contain or standardise the same mixture.[5]

A food recipe and a supplement capsule are also not interchangeable. The NIH explains that teas, tinctures and extracts vary in strength, and that US supplements are not legally required to be standardised.[6]

Quality: what to look for

Saffron is the dried stigma, or thread, of Crocus sativus. Affron is a branded stigma extract standardised to more than 3.5% Lepticrosalides, a measure covering crocin and safranal compounds.[3] An unspecified “saffron complex” gives you less to inspect.

Look for independent batch testing. USP, NSF or ConsumerLab can test identity, purity, strength and contamination, although a seal does not prove benefit for a particular symptom. US law does not require supplements to be standardised, so “standardised” alone is not a quality award.[6]

Pemi Luna uses 28 mg of Affron in its strip, plus L-theanine and B6. That matches the perimenopause Affron dose, but the strip has not been clinically tested.

Safety and the boundary

Short-term studies generally report mild effects such as headache, nausea, appetite changes, anxiety or nervousness and sleep disturbance. The trials are small, and longer-term safety remains uncertain.[5] A one-week study of 200 or 400 mg daily found blood-pressure and laboratory changes, so high doses should not be extrapolated to a self-directed mood supplement.[7]

Pregnancy and breastfeeding are not the time to improvise. Supplement-level safety evidence is limited. Get advice first if you could be pregnant, are breastfeeding, have a hormone-sensitive condition or breast-cancer history, or take prescription medicines, antidepressants, blood-pressure medicines or blood thinners. Saffron’s possible effects on blood pressure, platelet aggregation and medicines are unsettled. Do not stop prescribed care for a spice.

Persistent sadness, panic, hopelessness, loss of interest, or thoughts of self-harm need medical care, not a supplement trial. The perimenopause depression guideline says antidepressants and psychotherapy remain front-line options for a major depressive episode; it does not position saffron as a replacement.[8]

The honest verdict

Saffron is a plausible mood supplement, not a proven perimenopause treatment. Its best direct evidence is 28 mg/day of Affron for 12 weeks, with improved psychological symptoms in one small trial. For general mood, the wider evidence is promising but inconsistent by outcome. Long-term safety is incomplete.

Summary

Saffron may modestly help some mood symptoms during perimenopause. One 12-week trial found 28 mg/day of standardised Affron improved psychological symptoms in 86 women, without improving hot flashes or broader quality of life. Most other trials studied adults with low mood or depression, and a 2026 review found benefits on self-reported measures but not clinician-rated mood scales. The best study match is 28 mg/day for 12 weeks; product form and standardisation matter. Short-term tolerability looks acceptable, but interactions, pregnancy, long-term safety and major depression need professional care.

Sources

1. Lopresti and Smith, Affron in perimenopausal women
2. Mahmoudi et al., GRADE-assessed systematic review of 34 randomised trials
3. Kell et al., 28 mg and 22 mg Affron in adults with low mood
4. Affron mood trial affiliations and funding record
5. Marx et al., systematic review of saffron for depression and anxiety
6. NIH Office of Dietary Supplements: botanical supplements, quality and safety
7. Modaghegh et al., short-term safety of 200 mg and 400 mg saffron
8. North American Menopause Society: perimenopausal depression guidelines